Journal of Immunobiology

Cancer immunotherapy has revolutionized the treatment landscape, with Immune Checkpoint Inhibitors (ICIs) playing a pivotal role in harnessing the body's immune system to combat cancer. However, not all patients respond equally to ICIs, necessitating the exploration of innovative strategies to enhance their effectiveness. This article explores the emerging field of using CRISPR-Cas9 gene editing technology to augment the therapeutic potential of ICIs. By targeting specific genes and pathways involved in immune response regulation, CRISPR holds the promise of improving the outcomes of cancer patients and advancing the future of precision medicine. Some cancer cells develop resistance to ICIs by upregulating alternative immune checkpoints. CRISPR can be employed to disrupt the expression of these checkpoints, making cancer cells more susceptible to ICI therapy. The tumor microenvironment plays a pivotal role in cancer progression and response to immunotherapy. CRISPR can be used to modify immune cells and stromal cells within the tumor microenvironment, promoting an immune-favorable environment and enhancing the response to ICIs.

Immunometabolism is a burgeoning field that explores the intricate connections between cellular metabolism and immune responses. Hypoxia- Inducible Factor (HIF) signaling pathways play a pivotal role in orchestrating the metabolic changes that underlie immune cell function. In this article, we delve into the fascinating interplay between hypoxia, HIFs and immunometabolism. We discuss how hypoxia influences immune cell metabolism and how HIFs act as key regulators of this process. Furthermore, we examine the implications of dysregulated HIF signaling in immune-related disorders and explore potential therapeutic avenues. Understanding the role of hypoxia and HIF signaling in immunometabolism is crucial for advancing our knowledge of immune system function and developing novel treatments for immune-mediated diseases.

The immune system is a complex network of cells and molecules that work in harmony to protect the body against pathogens and maintain tissue homeostasis. While the innate and adaptive arms of the immune system have traditionally been considered distinct, recent research has unveiled intricate interactions between these two branches. Innate Lymphoid Cells (ILCs), a relatively newly discovered subset of immune cells, play a pivotal role in mediating cross-talk between innate and adaptive immunity. This article explores the fascinating world of ILCs and their dynamic interactions with adaptive immune cells, shedding light on the profound implications of this cross-talk for immunological responses and potential therapeutic strategies. The discovery of innate lymphoid cells and their interactions with adaptive immunity has expanded our understanding of the immune system's complexity. This cross-talk not only shapes immune responses but also plays a critical role in maintaining tissue homeostasis and preventing immunopathologies.

The Tumor Microenvironment (TME) is a complex and dynamic ecosystem in which cancer cells interact with various stromal cells, immune cells and extracellular matrix components. One crucial aspect of these interactions is metabolic reprogramming. This article explores the intricate metabolic interactions that occur within the TME, shedding light on how these interactions drive tumor progression, immune evasion and potential therapeutic targets. Understanding the metabolic intricacies of the TME is crucial for developing novel cancer treatments and improving patient outcomes.